HALOZYME THERAPEUTICS, INC. Annual Income Tax Expense (Benefit) in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2014 to 2023.
  • Halozyme Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $28.1M, a 41.2% increase year-over-year.
  • Halozyme Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $87.6M, a 36.8% increase year-over-year.
  • Halozyme Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $66.7M, a 42.6% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $46.8M.
  • Halozyme Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$154M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $66.7M +$19.9M +42.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 $46.8M +$201M Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 -$154M* -$154M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-20
2020 $217K +$228K Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 -$11K -$548K -102% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-22
2018 $537K +$1.9M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-23
2017 -$1.36M -$2.52M -217% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-24
2016 $1.16M +$1.16M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-21
2015 $0 $0 Jan 1, 2015 Dec 31, 2015 10-K 2018-02-20
2014 $0 Jan 1, 2014 Dec 31, 2014 10-K 2017-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.